NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Escalation vs. Induction Therapy Strategy in Patients With Early-Onset MS After Age 50

RecruitingN/A

Sponsor: University Hospital, Strasbourg, France

Conditions: Multiple Sclerosis (MS)

Countries: France

The objective of this study is to evaluate the risk of inflammatory disease activity by retrospectively comparing two therapeutic strategies (escalation group and induction group). The investigators also aim to identify factors associated with inflammatory relapse and treatment-related complications.

Eligibility overview

Sex: ALL

Age: 50 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Patients with RRMS onset after age 50
* Patients who started their first disease-modifying therapy within 2 years of the first symptoms
* Patients Treated with moderately effective disease-modifying antirheumatic drugs (DMARDs) (teriflunomide, dimethyl fumarate or diroximel fumarate, glatiramer acetate, interferon beta, peginterferon)
* Patient treated with highly effective DMARDs (fingolimod, ponesimod, natalizumab, rituximab, ocrelizumab, ofatumumab, cladribine)

Exclusion Criteria:

\- Patients with early progressive MS

Locations (1)

Strasbourg, France